this trial does not suggest a benefit of the studied hip protector among people living outside residential accommodation.

No abstract

ObjectivesTo study delay in diagnosis, seizure control, seizure‐pro‐voking factors, suitable medications and drug side effects in patients with juvenile myoclonic epilepsy. DesignTelephone and personal interview of patients and review of their clinical notes. Participants and settingThirty‐six patients attending an epilepsy clinic at a tertiary referral hospital. ResultsThere was a substantial delay in the diagnosis of juvenile myoclonic epilepsy because the symptom of early‐morning myoclonus was not specifically sought. Sodium valproate is the drug of choice, producing absolute seizure control in 63% of cases (19/30). Most patients with poor seizure control had provoked seizures only, emphasising the importance of lifestyle in management. Half of the patients taking sodium valproate experienced side effects, such as weight gain. Lamotrigine is the most suitable alternative. ConclusionsJuvenile myoclonic epilepsy is a common, under‐recognised form of epilepsy which is best treated with sodium valproate. If side effects occur, lamotrigine should be used.

Action plans are still under-utilized in children with asthma. General practitioners should be encouraged to consider the use of action plans for the group of children not already covered.

Solvents for crystallisation were: A, light petroleum (b. p. 60-80"); B, ethanol; C, methanol; * Picrate, m. p. 169-170°; base purified by distillation, b. p. 200"/0.25 mm. t Pzep. from ethiodide by use of ion-exchange resin (De-acidite F.F.). The tartrate, m. p. 76-80 , showed maximum solubility in water at 60'. 3 Morpholino. 7 Distilled, b. p. 219-221"/0.4 mm.; hydrochloride, m. p. 205-207". ** With decornp. D, water; E , propan-2-01. 5 -ChZoro -2 -[4 -(3 -diethyZamino~ropoxy)phenyl]benzothiazoZe HydrochZoride.-2 -Amino-4-